[go: up one dir, main page]

MX2016001383A - Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab. - Google Patents

Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab.

Info

Publication number
MX2016001383A
MX2016001383A MX2016001383A MX2016001383A MX2016001383A MX 2016001383 A MX2016001383 A MX 2016001383A MX 2016001383 A MX2016001383 A MX 2016001383A MX 2016001383 A MX2016001383 A MX 2016001383A MX 2016001383 A MX2016001383 A MX 2016001383A
Authority
MX
Mexico
Prior art keywords
asthma
methods
benralizumab
exacerbation rates
reducing exacerbation
Prior art date
Application number
MX2016001383A
Other languages
English (en)
Other versions
MX368508B (es
Inventor
Wang Bing
Roskos Lorin
Ward Christine
Raible Donald
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2016001383A publication Critical patent/MX2016001383A/es
Publication of MX368508B publication Critical patent/MX368508B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Bathtubs, Showers, And Their Attachments (AREA)

Abstract

Se presentan los métodos para reducir las exacerbaciones de asma en un paciente con asma, que comprenden administrar al paciente una cantidad efectiva del anticuerpo benralizumab que actúa sobre el receptor de interleucina-5 (IL-5R) o un fragmento de unión al antígeno de este.
MX2016001383A 2013-08-12 2014-08-07 Benralizumab para usarse en la reducción de la tasa de exacerbación de asma. MX368508B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
PCT/US2014/050080 WO2015023504A1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab

Publications (2)

Publication Number Publication Date
MX2016001383A true MX2016001383A (es) 2016-08-03
MX368508B MX368508B (es) 2019-10-07

Family

ID=52448837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001383A MX368508B (es) 2013-08-12 2014-08-07 Benralizumab para usarse en la reducción de la tasa de exacerbación de asma.

Country Status (26)

Country Link
US (2) US9441037B2 (es)
EP (1) EP3033101B1 (es)
JP (4) JP6746495B2 (es)
KR (2) KR20220057637A (es)
CN (2) CN105451760A (es)
AU (2) AU2014306956B2 (es)
BR (1) BR112016002401A8 (es)
CA (1) CA2918105C (es)
CY (1) CY1122132T1 (es)
DK (1) DK3033101T3 (es)
ES (1) ES2716906T3 (es)
HK (1) HK1221644A1 (es)
HR (1) HRP20190405T1 (es)
HU (1) HUE042607T2 (es)
LT (1) LT3033101T (es)
ME (1) ME03348B (es)
MX (1) MX368508B (es)
PL (1) PL3033101T3 (es)
PT (1) PT3033101T (es)
RS (1) RS58404B1 (es)
RU (1) RU2676333C2 (es)
SG (2) SG11201600481UA (es)
SI (1) SI3033101T1 (es)
SM (1) SMT201900163T1 (es)
TR (1) TR201903312T4 (es)
WO (1) WO2015023504A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368474B (es) 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.
KR102337599B1 (ko) * 2013-08-12 2021-12-10 아스트라제네카 아베 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations
AU2015204674B2 (en) 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
JP2018538249A (ja) 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン
PL3565823T3 (pl) 2017-01-04 2024-10-28 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Peptydy S-arestyn oraz ich zastosowanie terapeutyczne
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK3072525T3 (en) * 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
CN102365017A (zh) * 2009-11-18 2012-02-29 美迪诺亚公司 哮喘急性恶化的治疗及减少哮喘患者住院治疗的可能性
KR101615474B1 (ko) * 2010-12-16 2016-04-25 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US20140328839A1 (en) 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
KR102337599B1 (ko) * 2013-08-12 2021-12-10 아스트라제네카 아베 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
MX368474B (es) 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.

Also Published As

Publication number Publication date
KR20160042121A (ko) 2016-04-18
EP3033101B1 (en) 2018-12-19
HUE042607T2 (hu) 2019-07-29
CA2918105A1 (en) 2015-02-19
KR102390714B1 (ko) 2022-04-26
ES2716906T3 (es) 2019-06-17
BR112016002401A2 (pt) 2017-09-12
RU2016108723A (ru) 2017-09-19
RU2676333C2 (ru) 2018-12-28
MX368508B (es) 2019-10-07
DK3033101T3 (en) 2019-04-08
SG10202005560UA (en) 2020-07-29
BR112016002401A8 (pt) 2018-06-12
CA2918105C (en) 2023-02-28
TR201903312T4 (tr) 2019-04-22
WO2015023504A1 (en) 2015-02-19
ME03348B (me) 2019-10-20
SG11201600481UA (en) 2016-02-26
CN105451760A (zh) 2016-03-30
AU2014306956A1 (en) 2016-02-04
JP2024129139A (ja) 2024-09-26
EP3033101A4 (en) 2017-07-12
WO2015023504A8 (en) 2015-09-24
JP2016527324A (ja) 2016-09-08
RS58404B1 (sr) 2019-04-30
JP6746495B2 (ja) 2020-08-26
HK1225302B (en) 2017-09-08
AU2014306956B2 (en) 2019-11-21
EP3033101A1 (en) 2016-06-22
US20170198049A1 (en) 2017-07-13
CY1122132T1 (el) 2020-11-25
AU2020201327A1 (en) 2020-03-12
RU2016108723A3 (es) 2018-06-18
JP2020128375A (ja) 2020-08-27
HK1221644A1 (zh) 2017-06-09
HRP20190405T1 (hr) 2019-04-19
JP2022120009A (ja) 2022-08-17
CN111588848A (zh) 2020-08-28
PL3033101T3 (pl) 2019-06-28
SI3033101T1 (sl) 2019-04-30
US20150044202A1 (en) 2015-02-12
SMT201900163T1 (it) 2019-05-10
KR20220057637A (ko) 2022-05-09
PT3033101T (pt) 2019-04-02
LT3033101T (lt) 2019-03-25
US9441037B2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
MX2016001383A (es) Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab.
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
SG194701A1 (en) Anti-cd40 antibodies and methods of use
MX381456B (es) Regulador de ph de transduccion.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
PH12014502406B1 (en) Anti-il-23p19 antibodies
TN2012000462A1 (en) Anti-cd40 antibodies
PH12016501366A1 (en) Novel anti-baff antibodies
JO3092B1 (ar) مركب لتحفيز مسيطر عليه للمبيض
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX360774B (es) Antagonistas de progesterona.
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.
TN2013000265A1 (en) Anti-cd38 antibodies

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ASTRAZENECA AB

FG Grant or registration